Captor Therapeutics Spolka Akcyjna Valuation
Is CTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CTX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CTX's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CTX?
Other financial metrics that can be useful for relative valuation.
What is CTX's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | zł371.66m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 25.6x |
Enterprise Value/EBITDA | -5x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CTX's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 4x | ||
MAB Mabion | 1.7x | 3.1% | zł263.1m |
SVE Synthaverse | 6x | n/a | zł349.1m |
BIO BIOTON | 1.7x | n/a | zł303.1m |
RDG Read-Gene | 6.5x | n/a | zł65.6m |
CTX Captor Therapeutics Spolka Akcyjna | 29.6x | 20.3% | zł371.7m |
Price-To-Sales vs Peers: CTX is expensive based on its Price-To-Sales Ratio (29.6x) compared to the peer average (4x).
Price to Earnings Ratio vs Industry
How does CTX's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Sales vs Industry: CTX is expensive based on its Price-To-Sales Ratio (29.6x) compared to the European Biotechs industry average (10x).
Price to Sales Ratio vs Fair Ratio
What is CTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 29.6x |
Fair PS Ratio | 6.1x |
Price-To-Sales vs Fair Ratio: CTX is expensive based on its Price-To-Sales Ratio (29.6x) compared to the estimated Fair Price-To-Sales Ratio (6.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | zł80.00 | zł115.00 +43.8% | 4.3% | zł120.00 | zł110.00 | n/a | 2 |
Apr ’25 | zł63.00 | zł115.00 +82.5% | 4.3% | zł120.00 | zł110.00 | n/a | 2 |
Mar ’25 | zł91.00 | zł127.50 +40.1% | 5.9% | zł135.00 | zł120.00 | n/a | 2 |
Feb ’25 | zł97.40 | zł127.50 +30.9% | 5.9% | zł135.00 | zł120.00 | n/a | 2 |
Jan ’25 | zł99.00 | zł127.50 +28.8% | 5.9% | zł135.00 | zł120.00 | n/a | 2 |
Dec ’24 | zł86.60 | zł160.00 +84.8% | 25.0% | zł200.00 | zł120.00 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.